NCT06957886View on ClinicalTrials.gov

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

564

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
HER2-low Breast Cancer
Interventions
DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel

Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.

Trial Locations (2)

Unknown

RECRUITING

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY